Novo Nordisk's GLP-1 dominance fades as Eli Lilly surges ahead

Novo Nordisk, a long-time leader in diabetes and weight-loss drugs, is facing growing pressure from rival Eli Lilly. Over the past three years, its dominance in the GLP-1 market has slipped, with projections now showing a revenue decline by 2026. Despite this, the company remains a major player with a strong pipeline and steady dividend returns.

Between 2023 and 2025, Novo Nordisk's share of the stock market today GLP-1 market fell from around 65% to 45%. Supply shortages for its key drugs, Ozempic and Wegovy, opened the door for Eli Lilly to gain ground. Lilly's Mounjaro and Zepbound, both based on tirzepatide, proved more effective for weight loss and scaled up production faster.

Novo Nordisk's next-generation treatment, CagriSema, also underperformed in trials compared to Lilly's Zepbound. This setback comes as the company tries to diversify its offerings, with several new candidates in its pipeline awaiting approval.

While Novo Nordisk has led the diabetes drug market for decades, its recent stock market performance has lagged behind broader market trends. Analysts note that turning a $100,000 investment into $1 million in ten years would require a 25.89% annual return—a target considered unrealistic even under ideal conditions. The company's pricing power may also face limits due to rising competition.

Novo Nordisk still holds a strong position in the GLP-1 sector, which is expected to expand significantly over the next decade. Its deep pipeline and dividend returns could make it a viable long-term investment. However, the company's shrinking stock market share and revenue outlook suggest a more challenging road ahead.